Preneoplastic changes persist after IGF-IR downregulation and tumor regression

Oncogene

Volumn 29, Issue 34, 2010, Pages 4779-4786

  Jones, R A ^a   Petrik, J J ^a   Moorehead, R A ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

dormant tumor cells; IGF IR; mammary tumorigenesis; tumor recurrence; tumor regression

Indexed keywords

DOXYCYCLINE; LIPOFUSCIN; SOMATOMEDIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CARCINOGENESIS; DOWN REGULATION; HISTOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENE; TUMOR RECURRENCE; TUMOR REGRESSION; ANIMAL; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PRECANCER; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; PRECANCEROUS CONDITIONS; RECEPTOR, IGF TYPE 1; TRANSGENES;

MUS;

EID: 77956170799     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.231     Document Type: Article

References (36)

1. 4779-4786Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr. FC, AllredDC et al. (1989). Blockade of the type I somatomedin receptorinhibits growth of human breast cancer cells in athymic mice. J ClinInvest 84: 1418-1423.
2. Arteaga CL, Osborne CK. (1989). Growth inhibition of human breastcancer cells in vitro with an antibody against the type I somatomedinreceptor. Cancer Res 49: 6237-6241.
3. Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY et al.(2009). Residual breast cancer diagnosed by MRI in patientsreceiving neoadjuvant chemotherapy with and without bevacizumab.Ann Surg Oncol 16: 1619-1628.
4. Baserga R, Peruzzi F, Reiss K. (2003). The IGF-1 receptor in cancerbiology. Int J Cancer 107: 873-877.
5. Bates P, Fisher R, Ward A, Richardson L, Hill DJ,Graham CF. (1995). Mammary cancer in transgenic miceexpressing insulin-like growth factor II (IGF-II). Br J Cancer 72:1189-1193.
6. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J,Southern EM et al. (2003). The efficacy of small interfering RNAstargeted to the type 1 insulin-like growth factor receptor (IGF1R) isinfluenced by secondary structure in the IGF1R transcript. J BiolChem 278: 15991-15997.
7. Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. (1997).Overexpression of insulin-like growth factor-1 induces hyperplasia,dermal abnormalities, and spontaneous tumor formation intransgenic mice. Oncogene 14: 1725-1734.
8. Carboni JM, Lee AV, Hadsell DL, Rowley BR, Lee FY, Bol DK et al.(2005). Tumor development by transgenic expression of a constitutivelyactive insulin-like growth factor I receptor. Cancer Res 65:3781-3787.
9. Chernicky CL, Tan H, Yi L, Loret Jr. dM, Ilan J. (2002). Treatment ofmurine breast cancer cells with antisense RNA to the type I insulinlikegrowth factor receptor decreases the level of plasminogenactivator transcripts, inhibits cell growth in vitro, and reducestumorigenesis in vivo. Mol Pathol 55: 102-109.
10. Denys H, Braems G, Lambein K, Pauwels P, Hendrix A, De BA et al.(2009). The extracellular matrix regulates cancer progression andtherapy response: implications for prognosis and treatment. CurrPharm Des 15: 1373-1384.
11. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran Let al. (2000). Deregulated expression of insulin-like growth factor 1in prostate epithelium leads to neoplasia in transgenic mice. ProcNatl Acad Sci USA 97: 3455-3460.
12. Ghajar CM, Bissell MJ. (2008). Extracellular matrix control ofmammary gland morphogenesis and tumorigenesis: insights fromimaging. Histochem Cell Biol 130: 1105-1118.
13. Gualberto A, Pollak M. (2009). Emerging role of insulin-like growthfactor receptor inhibitors in oncology: early clinical trial results andfuture directions. Oncogene 28: 3009-3021.
14. Hadsell DL, Murphy KL, Bonnette SG, Reece N, Laucirica R,Rosen JM. (2000). Cooperative interaction between mutant p53 anddes(1-3)IGF-I accelerates mammary tumorigenesis. Oncogene 19:889-898.
15. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M et al.(2002). Sustained loss of a neoplastic phenotype by brief inactivationof MYC. Science 297: 102-104.
16. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, KhokhaR et al. (2007). Transgenic overexpression of IGF-IR disruptsmammary ductal morphogenesis and induces tumor formation.Oncogene 26: 1636-1644.
17. Jones RA, Campbell CI, Wood GA, Petrik JJ, Moorehead RA. (2009).Reversibility and recurrence of IGF-IR-induced mammary tumors.Oncogene 28: 2152-2162.
18. Kaplan-Lefko PJ, Sutherland BW, Evangelou AI, Hadsell DL, BarriosRJ, Foster BA et al. (2008). Enforced epithelial expression of IGF-1causes hyperplastic prostate growth while negative selection isrequisite for spontaneous metastogenesis. Oncogene 27: 2868-2876.
19. LeRoith D, Roberts Jr. CT. (2003). The insulin-like growth factorsystem and cancer. Cancer Lett 195: 127-137.
20. Linnerth NM, Siwicky MD, Campbell CI, Watson KL, Petrik JJ,Whitsett JA et al. (2009). Type I insulin-like growth factor receptorinduces pulmonary tumorigenesis. Neoplasia 11: 672-682.
21. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. (2001). Insulin-likegrowth factor-I receptor signaling and resistance to trastuzumab(Herceptin). J Natl Cancer Inst 93: 1852-1857.
22. Miranda MB, Duan R, Thomas SM, Grandis Jr., Redner RL, JonesJE et al. (2008). Gefitinib potentiates myeloid cell differentiation byATRA. Leukemia 22: 1624-1627.
23. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R. (2003).Transgenic overexpression of IGF-II induces spontaneous lungtumors: a model for human lung adenocarcinoma. Oncogene 22:853-857.
24. Morris GJ, Robinson PA, Lo S, Samuel TA, Sheikh AA, Jordan IIIWE et al. (2010). Residual disease after neoadjuvant chemotherapyfor breast cancer. Semin Oncol 37: 1-10.
25. Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action andresistance. Cancer Lett 232: 123-138.
26. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. (2005).Insulin-like growth factor-I receptor/human epidermal growthfactor receptor 2 heterodimerization contributes to trastuzumabresistance of breast cancer cells. Cancer Res 65: 11118-11128.
27. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L,Symmans WF. (2008). Residual specimen cellularity after neoadjuvantchemotherapy for breast cancer. Br J Surg 95: 433-437.
28. Pravtcheva DD, Wise TL. (1998). Metastasizing mammarycarcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool281: 43-57.
29. Pure E. (2009). The road to integrative cancer therapies: emergence ofa tumor-associated fibroblast protease as a potential therapeutictarget in cancer. Expert Opin Ther Targets 13: 967-973.
30. Sachdev D, Yee D. (2001). The IGF system and breast cancer. EndocrRelat Cancer 8: 197-209.
31. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, BajamondeA et al. (2001). Use of chemotherapy plus a monoclonal antibodyagainst HER2 for metastatic breast cancer that overexpressesHER2. N Engl J Med 344: 783-792.
32. Surmacz E. (2000). Function of the IGF-I receptor in breast cancer.J Mam Gland Biol Neoplasia 5: 95-105.
33. Surmacz E. (2003). Growth factor receptors as therapeutic targets:strategies to inhibit the insulin-like growth factor I receptor.Oncogene 22: 6589-6597.
34. Wilker E, Lu J, Rho O, Carbajal S, Beltran L, DiGiovanni J. (2005).Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1)skin tumor promotion. Mol Carcinog 44: 137-145.
35. Wise TL, Pravtcheva DD. (2006). Delayed onset of Igf2-inducedmammary tumors in Igf2r transgenic mice. Cancer Res 66:1327-1336.
36. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, CristofanilliM, Liu P et al. (2009). Epidermal growth factor receptor tyrosinekinase inhibitor reverses mesenchymal to epithelial phenotype andinhibits metastasis in inflammatory breast cancer. Clin Cancer Res15: 6639-6648.